Latest Clinical research Stories

Partnerships In Clinical Trials Nominates Christine Pierre for Clinical Trial Business Woman of the Year

2013-04-10 16:26:24

President of the Society for Clinical Research Sites Recognized for Innovative Work ROCKVILLE, Md., April 10, 2013 /PRNewswire/ -- The Society for Clinical Research Sites (SCRS) is pleased to announce that President Christine Pierre has been nominated for the Clinical Trial Business Woman of the Year Award. This prestigious award, granted by the Partnerships in Clinical Trials (PCT), recognizes a woman who has exemplified strong and innovative leadership and has set an example to...

2013 Chinese Pharmaceutical Guidebook: Drug Registration Rules

2013-04-10 12:27:29

MarketReportsOnline.com offers the latest guidebook for application of imported traditional Chinese medicine and natural medicine registration DALLAS, April 10, 2013 /PRNewswire-iReach/ -- China Pharmaceutical Guidebook Series (1) 2013 Edition Latest Chinese Regulations for Imported Drug Registration: A Comprehensive Guidebook for Foreign Pharmaceutical Companies By 2012, sales on the Chinese drug market have reached RMB 926.1billion (about US$147 billion) reported by the "2012:...

Moravia Provides Guidance to Life Sciences Sector as Croatia Nears EU Accession and European Medicines Agency Deadlines Loom

2013-04-10 12:24:16

Accession highlights international business opportunity and complexity as industry faces new regulatory standards in Croatia NEWBURY PARK, Calif., April 10, 2013 /PRNewswire/ -- As Croatia prepares to join the European Union (EU) on July 1, global and regional life sciences companies are facing regulatory and compliance deadlines in accordance with EU European Medicines Agency (EMA) standards. (Logo: http://photos.prnewswire.com/prnh/20121012/DA92092LOGO) The EMA...

Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics (UK) Ltd.

2013-04-09 23:03:15

Inflamax Research Inc. today announced that it has been selected by Allergy Therapeutics (UK) Ltd. (ATL) (AGY:LSE), as the CRO to conduct ATL’s pivotal Phase III study for Grass MATAMPL product for US-FDA registration. Toronto, ON (PRWEB) April 09, 2013 The study will involve the location of mobile EEC at centers in three metropolitan areas in the US Midwest, US North East and in Canada, with several investigative sites at each node contributing subjects to the study. The screening and...

Patient-Centered Outcomes Research Institute Roundtable: Building a National Data Infrastructure to Advance Comparative Effectiveness Research

2013-04-09 16:24:06

PCORI to fund development of national data networks to facilitate patient-centered CER WASHINGTON, April 9, 2013 /PRNewswire-USNewswire/ -- The Patient-Centered Outcomes Research Institute (PCORI) will convene an April 23 roundtable discussion on how to create a national data infrastructure to support high-quality patient-centered comparative clinical effectiveness research (CER). The roundtable will accompany PCORI's release of two funding announcements committing $72 million to...

UK-Based West Midlands Regional Genetics Laboratory (WMRGL) Selects Cartagenia BENCHlab CNV Solution for Clinical Data Storage, Analysis

2013-04-09 12:30:09

BOSTON and BIRMINGHAM, England, April 9, 2013 /PRNewswire/ -- Cartagenia, the world leader in providing genetic labs and clinicians software-based workflow support for variant assessment, lab reporting, and integration of diagnostic knowledge-bases, announced today that it has signed a license agreement for its cloud-based BENCHlab CNV solution for genetic variant storage and analysis with West Midlands Regional Genetics Laboratory (WMRGL) at Birmingham Women's Hospital NHS Foundation...

Surveyed U.S. Pulmonologists Expect to Treat Nearly 50 Percent of Their Severe, Refractory Asthma Patients With a Biologic or Biosimilar Version of Xolair By the End of 2018

2013-04-09 08:31:40

Surveyed Payers Expect to Restrict the Prescribing of Emerging Biologics Through Controls Similar to Xolair, Limiting Patient Access, According to a New Report from Decision Resources BURLINGTON, Mass., April 9, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. pulmonologists estimate that only 19 percent of their severe, refractory asthma patients are treated with...

2013-04-08 12:23:32

Innovator Companies Expected to Lose Significant Revenue Due to Biosimilar Erosion, According to a New Report from BioTrends Research Group EXTON, Pa., April 8, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, with sales forecasted to exceed $16.8 billion by 2021, manufacturers competing in the biosimilars market must adopt clear and effective strategies early in product...

- Unigene Secures Financing to Extend Operating Runway in Conjunction with Strategic Reorganization -

2013-04-08 08:30:45

- Victory Park Capital Commences Process for Potential Sale of Peptelligence(TM) Drug Delivery Platform - BOONTON, N.J., April 8, 2013 /PRNewswire/ -- Unigene Laboratories, Inc. (PINK: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced that the Company has entered into a second amendment to a financing agreement with affiliates of Victory Park Capital Advisors, LLC (VPC), whereby VPC has agreed to purchase an additional...

Industry group supports uniform approach to transparency of clinical trial data

2013-04-05 16:23:17

NEW YORK, April 5, 2013 /PRNewswire/ -- As part of an ongoing industry-wide commitment to ensuring transparency in clinical studies, a group of pharmaceutical and biotechnology companies*, including AbbVie, AstraZeneca Pharmaceuticals LP, BiogenIdec, Bristol-Myers Squibb, EMD Serono, GlaxoSmithKline, Janssen, the Pharmaceutical Companies of Johnson & Johnson, Eli Lilly and Company, Merck & Co., Inc., Novartis, Novo Nordisk A/S, Roche, and Takeda Pharmaceuticals International,...